Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
December 15, 2020
Cellectis S.A. (CLLS) cancels $100 M ADS (American Depositary Shares) offering
December 11, 2020
Solid Biosciences (SLDB) executes a $90 M Private Placement
December 2, 2020
Intellia Therapeutics (NTLA) prices 4.79 million share offering at $36.50
November 4, 2020
Bellicum Pharmaceuticals (BLCM) closes 1.04 M share offering
September 15, 2020
Q2/20 Earnings - (LPS - loss-per-share) Results
August 12, 2020
Adverum Biotechnologies (ADVM) closes $216.8 million offering priced at $3.00
July 8, 2020
BioLife Solutions (BLFS) closes 5.95 million share offering priced at $14.50
July 2, 2020
MiMedx Group (OTC PINK: MDXG closed $150 million private equity and debt financings
June 26, 2020
Editas Medicine (EDIT) closes 6.9 million shares offering at $31.25
June 6, 2020
Intellia Therapeutics (NTLA) closes $115 million offering
May 30, 2020
RegMed/Cell and Gene Therapy Earnings Scorecard - Q1/20 - to date
May 26, 2020
RegMed Investor (RMi) … Q1/2020 earnings reporting dates
May 26, 2020
Caladrius Biosciences, Inc. (CLBS) closes RDO (registered direct offering) of 2.084 million shares priced at $2.06
May 19, 2020
bluebird bio (BLUE) proposes 9.09 M share offering priced at $55.00
May 13, 2020
Mesoblast (MESO ASX: MSB) completes US$90 M private placement of 43 M shares
May 11, 2020
bluebird bio (BLUE) to receive $200 M from Bristol Meyers Squibb (BMY)
May 10, 2020
MiMedx (OTC PINK: MDXG) pays back PPP Loan
May 5, 2020
Pluristem Therapeutics (PSTI) initiates a Registered Direct Offering (RDO)
May 1, 2020
RegMed Investors (RMi): April - a roller coaster month ends
April 11, 2020
Regenerative Medicine Earnings Scorecard - Q4 & FY19
April 10, 2020
Sangamo Therapeutics (SGMO) closed its Biogen (BIIB) collaboration agreement
April 7, 2020
Sage Therapeutics (SAGE) Restructuring
March 30, 2020
Athersys (ATHX); HEALIOS K.K., its partner in Japan exercised in full its 4 million warrants to purchase shares at $1.76
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2021 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.